Cargando…

Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center

Paraneoplastic syndromes are rare conditions associated with characteristic autoantibodies produced by malignancy, although similar autoantibodies and clinical presentations may occur in the absence of any neoplasm. Testing for paraneoplastic syndromes often involves panels of autoantibody assays. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasowski, Matthew D., Dolezal, Anna, Steussy, Bryan W., Gailey, Michael P., Darbro, Benjamin W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627986/
https://www.ncbi.nlm.nih.gov/pubmed/34877371
http://dx.doi.org/10.1016/j.dib.2021.107578
_version_ 1784606927368486912
author Krasowski, Matthew D.
Dolezal, Anna
Steussy, Bryan W.
Gailey, Michael P.
Darbro, Benjamin W.
author_facet Krasowski, Matthew D.
Dolezal, Anna
Steussy, Bryan W.
Gailey, Michael P.
Darbro, Benjamin W.
author_sort Krasowski, Matthew D.
collection PubMed
description Paraneoplastic syndromes are rare conditions associated with characteristic autoantibodies produced by malignancy, although similar autoantibodies and clinical presentations may occur in the absence of any neoplasm. Testing for paraneoplastic syndromes often involves panels of autoantibody assays. While autoantibody testing may reveal or confirm actionable clinical diagnoses, inappropriate utilization of testing may be low yield and further lead to false positives that may confuse the clinical picture. There is thus opportunity to improve patient care by analyzing patterns of paraneoplastic autoantibody test utilization. The data in this article provides results from detailed retrospective review of patients tested by 7 autoantibody tests or test panels offered by two large reference laboratories in the United States. The data include 1,446 tests performed on 1,338 unique patients at an academic medical center. For all results, detailed chart review revealed main category of presenting symptoms, patient location at time of testing (either inpatient or outpatient), sex, age, whether cancer was present at the time of testing or later detected, and the specific results of the testing. The data are summarized by category of testing and specific autoantibodies.
format Online
Article
Text
id pubmed-8627986
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86279862021-12-06 Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center Krasowski, Matthew D. Dolezal, Anna Steussy, Bryan W. Gailey, Michael P. Darbro, Benjamin W. Data Brief Data Article Paraneoplastic syndromes are rare conditions associated with characteristic autoantibodies produced by malignancy, although similar autoantibodies and clinical presentations may occur in the absence of any neoplasm. Testing for paraneoplastic syndromes often involves panels of autoantibody assays. While autoantibody testing may reveal or confirm actionable clinical diagnoses, inappropriate utilization of testing may be low yield and further lead to false positives that may confuse the clinical picture. There is thus opportunity to improve patient care by analyzing patterns of paraneoplastic autoantibody test utilization. The data in this article provides results from detailed retrospective review of patients tested by 7 autoantibody tests or test panels offered by two large reference laboratories in the United States. The data include 1,446 tests performed on 1,338 unique patients at an academic medical center. For all results, detailed chart review revealed main category of presenting symptoms, patient location at time of testing (either inpatient or outpatient), sex, age, whether cancer was present at the time of testing or later detected, and the specific results of the testing. The data are summarized by category of testing and specific autoantibodies. Elsevier 2021-11-18 /pmc/articles/PMC8627986/ /pubmed/34877371 http://dx.doi.org/10.1016/j.dib.2021.107578 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Data Article
Krasowski, Matthew D.
Dolezal, Anna
Steussy, Bryan W.
Gailey, Michael P.
Darbro, Benjamin W.
Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center
title Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center
title_full Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center
title_fullStr Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center
title_full_unstemmed Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center
title_short Data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center
title_sort data on the utilization of paraneoplastic syndrome autoantibody testing at an academic medical center
topic Data Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627986/
https://www.ncbi.nlm.nih.gov/pubmed/34877371
http://dx.doi.org/10.1016/j.dib.2021.107578
work_keys_str_mv AT krasowskimatthewd dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter
AT dolezalanna dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter
AT steussybryanw dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter
AT gaileymichaelp dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter
AT darbrobenjaminw dataontheutilizationofparaneoplasticsyndromeautoantibodytestingatanacademicmedicalcenter